Results 11 to 20 of about 23,498 (195)

Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom. [PDF]

Neurol Ther
Introduction Tysabri (natalizumab) is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active relapsing-remitting multiple sclerosis (RRMS). A subcutaneous (SC) formulation administered by healthcare professionals (
De Cock E, Jomaa K, Menon J, Acosta C, Esquejo-Leon R, Oliver-Smith P.   +5 more
europepmc   +2 more sources

Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook. [PDF]

Ther Adv Neurol Disord
Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence
Klotz L, Berger T, Brownlee WJ, Chan A, Lycke J, Oreja-Guevara C, Palavra F, Sacca F, Sejbaek T, Weber MS, Giovannoni G.   +10 more
europepmc   +2 more sources

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report [PDF]

Journal of Medical Case Reports, 2009
Introduction Natalizumab is a new treatment for relapsing-remitting multiple sclerosis. Because of limited experience of this treatment, medical professionals must be alert to possible side effects.
Stylianos Gatzonis, Anna Siatouni
core   +4 more sources

Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis

Frontiers in Neurology, 2021
Background and Purpose: Natalizumab is a highly efficacious disease-modifying therapy for relapsing-remitting multiple sclerosis (MS). Data on the efficacy and safety profile of natalizumab in Asian patients with MS are limited.
Ki Hoon Kim, Su-Hyun Kim, Na Young Park, Jae-Won Hyun, Ho Jin Kim   +4 more
doaj   +1 more source

Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile

Arquivos de Neuro-Psiquiatria, 2021
Background: The real-world effectiveness of natalizumab in people with relapsing multiple sclerosis (PwRMS) in Argentina and Chile has not been reported.
Maria Celica Ysrraelit, Alejandro Caride, Vladimiro Sinay, Mario Rivera Kindel, Mario Javier Halfon, Liliana Patrucco, Raul Piedrabuena, Vanina Eleonor Diaz Aragunde   +7 more
doaj   +1 more source

Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis. [PDF]

PLoS ONE, 2012
Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) and interferes with immune cell migration into the central nervous system by blocking the α(4) subunit of very-late activation ...
Andrea Harrer, Georg Pilz, Max Einhaeupl, Katrin Oppermann, Wolfgang Hitzl, Peter Wipfler, Johann Sellner, Stefan Golaszewski, Shahrzad Afazel, Elisabeth Haschke-Becher, Eugen Trinka, Joerg Kraus   +11 more
doaj   +1 more source

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses

Frontiers in Neurology, 2021
Background: Plasma concentration of natalizumab falls above the therapeutic threshold in many patients who, therefore, receive more natalizumab than necessary and have higher risk of progressive multifocal leukoencephalopathy.Objective: To assess in a ...
Jose M. Serra López-Matencio, Yaiza Pérez García, Virginia Meca-Lallana, Raquel Juárez-Sánchez, Angeles Ursa, Lorena Vega-Piris, Dora Pascual-Salcedo, Annick de Vries, Theo Rispens, Cecilia Muñoz-Calleja, Cecilia Muñoz-Calleja   +10 more
doaj   +1 more source

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020
Objective To determine multiple sclerosis patient characteristics that predict a shorter duration of natalizumab treatment. Methods The Tysabri Outreach: Unified Commitment to Health database was reviewed to identify patients treated with natalizumab at ...
Devon S Conway, Carrie M Hersh, Haleigh C Harris, Le H Hua   +3 more
doaj   +1 more source

Effects of natalizumab treatment on Foxp3+ T regulatory cells.

PLoS ONE, 2008
BackgroundNatalizumab, a monoclonal humanized antibody targeting the alpha-4 chain of very late activation antigen 4 (VLA-4) exerts impressive therapeutic effects in patients with relapsing-remitting multiple sclerosis. Our objective was to study impacts
Max-Philipp Stenner, Anne Waschbisch, Dorothea Buck, Sebastian Doerck, Hermann Einsele, Klaus V Toyka, Heinz Wiendl   +6 more
doaj   +1 more source

Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis

Journal of Central Nervous System Disease, 2023
Background Changes in brain connectivity occur in patients with multiple sclerosis (MS), even in patients under disease-modifying therapies. Using magnetic resonance imaging (MRI) to asses patients treated with disease-modifying therapies, such as ...
Diogo G. Corrêa, Eelco van Duinkerken, João Gabriel D. Farinhas, Valéria C. Pereira, Emerson L. Gasparetto, Soniza V. Alves-Leon, Fernanda Cristina R. Lopes   +6 more
doaj   +1 more source